Mark Pomerantz, MD
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract (NCT02925533) | Mark Pomerantz, MD | 2016-12-14 |
Track Mark Pomerantz, MD automatically
Every clearance here is in the API, with alerts when new ones post.